CSI Market
Sign In | Register

Pacira Biosciences inc (PCRX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PCRX quarterly Cash Flow →
Examining cash flow movements between Pacira Biosciences inc and Dec 31 2021 reveals how Dec 31 2025 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income7.03
Depreciation & amortization91.02
Amortization of Other Assets3.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability23.69
Provision For Loan Losses Expensed-5.52
Increase (Decrease) in Inventories-27.57
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation57.50
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.98
Adjustments From Changes In Deferred Tax Asset Valuation Allowance Increase Decrease-
Equity Method Investment Other Than Temporary Impairment11.00
Gain Loss On Termination Of Lease-
Income taxes6.48
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable-3.89
Increase (Decrease) in Accounts Payable-5.60
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.21
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.93
Discontinued operations0.00
Net Cash flow from Operating Activities151.99
Investing Activities
Capital Expenditures-15.33
Sale of Capital Items0.00
Proceeds from Sale of Short-term Investments132.77
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Payment Of Contingent Consideration-
Payment For Contingent Consideration Liability Investing Activities-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments-1.25
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired-16.70
Proceeds from Sale of Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities99.48
Financing Activities
Short-term debt Net91.00
Other borrowing transactions-2.19
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-147.83
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-314.88
Proceeds From Stock Options And Warrants Exercised-
Stock Issued During Period Proceeds Followon Public Offering Issues-
Proceeds From Shares Issued Under Employee Stock Purchase Plan-
Proceeds from Shares Issued Under Employee Stock Purchase Plans-
Conversionofprincipalandequitycomponentofconvertibleseniornotes-
Increase Decrease In Contingent Consideration-
Increase Decreasein Accrued Fixed Assets-
Proceeds From Convertible Option Component Of Convertible Debt-
Proceeds From Shares Issued Under Employee Stock Purchase Plans2.80
Capital Expenditures Incurred But Not Yet Paid1.47
Payments For Debt Conversion Premiums-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-369.63
Effect of exchange rate on cash flow-0.08
Discontinued operations0.00
Free Cash Flow136.66
Total Cash Flow-118.23
4 historic quarters locked

Sign in to unlock the full Pacira Biosciences inc cash flow history.

Sign In Create Free Account

About Pacira Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: pcrx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-012297

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License